NI201000095A - Peptidomimeticos con actividades antagónistas de glucagon y agonistas del peptido 1 tipo glucagon. - Google Patents

Peptidomimeticos con actividades antagónistas de glucagon y agonistas del peptido 1 tipo glucagon.

Info

Publication number
NI201000095A
NI201000095A NI201000095A NI201000095A NI201000095A NI 201000095 A NI201000095 A NI 201000095A NI 201000095 A NI201000095 A NI 201000095A NI 201000095 A NI201000095 A NI 201000095A NI 201000095 A NI201000095 A NI 201000095A
Authority
NI
Nicaragua
Prior art keywords
glucagon
peptidomimetics
agonists
peptide
type
Prior art date
Application number
NI201000095A
Other languages
English (en)
Inventor
H Bahekar Rajesh
R Jain Mukul
Ramanbhai Patel Pankaj
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of NI201000095A publication Critical patent/NI201000095A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La presente invención proporciona peptidomiméticos novedosos , de la fórmula (I), los cuales actúan primariamente como secretagogos de insulina dependientes de glucosa. además, se encontró que estos peptidomiméticos muestran actividad antagonista del receptor de glucagón, junto con la actividad agonista del receptor GLP-1. A -Z1 - Z2 - Z3 - Z4 - Z5 - Z6 - Z7 - Z8 - Z9 - Z10 - Z11 - B (I)
NI201000095A 2007-12-11 2010-06-09 Peptidomimeticos con actividades antagónistas de glucagon y agonistas del peptido 1 tipo glucagon. NI201000095A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2420MU2007 2007-12-11
IN1696MU2008 2008-08-11

Publications (1)

Publication Number Publication Date
NI201000095A true NI201000095A (es) 2011-05-04

Family

ID=41066190

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201000095A NI201000095A (es) 2007-12-11 2010-06-09 Peptidomimeticos con actividades antagónistas de glucagon y agonistas del peptido 1 tipo glucagon.

Country Status (15)

Country Link
US (1) US8883963B2 (es)
EP (1) EP2231701B1 (es)
JP (1) JP5270687B2 (es)
KR (1) KR101277560B1 (es)
AT (1) ATE554098T1 (es)
CA (1) CA2707448C (es)
DK (1) DK2231701T3 (es)
EA (1) EA018000B1 (es)
ES (1) ES2382579T3 (es)
IL (1) IL206252A0 (es)
MX (1) MX2010006287A (es)
NI (1) NI201000095A (es)
PT (1) PT2231701E (es)
WO (1) WO2009125424A2 (es)
ZA (1) ZA201003804B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011048614A2 (en) 2009-10-22 2011-04-28 Cadila Healthcare Limited Short chain peptidomimetics based orally active glp-1 agonist and glucagon receptor antagonist
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
SG191040A1 (en) 2010-12-23 2013-08-30 Pfizer Glucagon receptor modulators
RS55225B1 (sr) 2011-02-08 2017-02-28 Pfizer Modulator glukagon receptora
ES2550345T3 (es) 2011-07-22 2015-11-06 Pfizer Inc. Moduladores del receptor de quinolinilglucagón
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2014049610A2 (en) * 2012-09-26 2014-04-03 Cadila Healthcare Limited Peptides as gip, glp-1 and glucagon receptors triple-agonist
CN105142621A (zh) 2012-10-24 2015-12-09 国家健康科学研究所 用于预防或治疗糖尿病和促进β-细胞存活的TPL2激酶抑制剂
EP3080153A2 (en) * 2013-12-13 2016-10-19 Medimmune Limited Protease resistant peptides
US10189884B2 (en) 2014-04-28 2019-01-29 The Trustees Of The University Of Pennsylvania Thioamide-modified peptides and uses thereof
EP3273981B1 (en) 2015-03-24 2020-04-29 INSERM - Institut National de la Santé et de la Recherche Médicale Method and pharmaceutical composition for use in the treatment of diabetes
TWI726889B (zh) 2015-06-10 2021-05-11 英商梅迪繆思有限公司 蛋白酶抗性之脂化肽

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR036711A1 (es) * 2001-10-05 2004-09-29 Bayer Corp Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
IL160917A0 (en) * 2001-10-18 2004-08-31 Bristol Myers Squibb Co Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
MX2007013655A (es) 2005-05-05 2008-01-24 Cadila Healthcare Ltd Nuevos compuestos como agonistas glp-i.
JP2008539735A (ja) * 2005-05-06 2008-11-20 バイエル・フアーマシユーチカルズ・コーポレーシヨン グルカゴン様ペプチド１（ｇｌｐ−１）受容体アンタゴニストおよびそれらの薬理学的使用方法
WO2007082264A2 (en) * 2006-01-11 2007-07-19 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
US20100022457A1 (en) * 2006-05-26 2010-01-28 Bristol-Myers Squibb Company Sustained release glp-1 receptor modulators
DK2084182T3 (da) * 2006-10-03 2013-11-04 Cadila Healthcare Ltd Antidiabetiske forbindelser

Also Published As

Publication number Publication date
KR20100101110A (ko) 2010-09-16
ZA201003804B (en) 2011-01-26
EP2231701B1 (en) 2012-04-18
MX2010006287A (es) 2010-10-26
JP5270687B2 (ja) 2013-08-21
EA201070722A1 (ru) 2010-12-30
CA2707448A1 (en) 2009-10-15
EP2231701A2 (en) 2010-09-29
DK2231701T3 (da) 2012-05-21
EA018000B1 (ru) 2013-04-30
PT2231701E (pt) 2012-05-28
US8883963B2 (en) 2014-11-11
IL206252A0 (en) 2010-12-30
CA2707448C (en) 2014-10-14
WO2009125424A3 (en) 2009-12-23
ATE554098T1 (de) 2012-05-15
US20120021972A1 (en) 2012-01-26
ES2382579T3 (es) 2012-06-11
WO2009125424A2 (en) 2009-10-15
JP2011506428A (ja) 2011-03-03
KR101277560B1 (ko) 2013-06-25

Similar Documents

Publication Publication Date Title
NI201000095A (es) Peptidomimeticos con actividades antagónistas de glucagon y agonistas del peptido 1 tipo glucagon.
MX2009003400A (es) Compuestos antidiabeticos.
NZ740644A (en) Glucagon receptor agonists
CL2011002942A1 (es) Compuestos derivados de 2,4-diamino-pirimidina, agonistas de receptor tipo toll-7 (tlr7); composicion farmaceutica; y su uso para el tratamiento del cancer.
EA201490070A1 (ru) Коантагонисты глюкагонового рецептора/glp-1-рецептора
MD3242887T2 (ro) Compuși co-agonişti ai GIP și GLP-1
CY1119361T1 (el) 3,4-διυδροισοκινολιν-2(1h)-υλικες ενωσεις
MY186712A (en) Methods and compositions for inhibiting the interaction of menin with mll proteinss
ECSP099225A (es) Compuestos antagonistas del receptor de glucagón, composiciones que contienen dichos compuestos y procedimientos de uso
CO6400136A2 (es) Agosnistas del receptor gpr120 y usos de los mismos
CR20110201A (es) Agonistas del receptor gpr120 de arilo y usos de los mismos
CL2015000942A1 (es) Compuestos de benceno sustituido.
EA201690629A1 (ru) Соединения, которые представляют собой тройные агонисты, глюкагона, glp-1 и gip
CR20130409A (es) Novedosos derivados de azabencimidazolcíclico útiles como agentes antidiabéticos
CL2012000583A1 (es) Compuestos derivados de quinazolinas sustituidas, inhibidores de los canales ionicos de potasio; composicion farmaceutica que los comprende; uso del compuesto para tratar o prevenir arritmias, controlar la frecuencia cardiaca, entre otras.
MX2013004307A (es) Derivados de arilamida como bloqueadores de ttx-s.
IL268444A (en) Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof
EA201390182A1 (ru) Соединения-агонисты рецептора glp-1, содержащие стабилизированные области
EP3957723A3 (en) Engineered ligase variants
CO6382139A2 (es) Anticuerpo anti-cmet novedoso
EA200702169A1 (ru) Профилактика вич-инфекции
MX366308B (es) Derivados de amida como bloqueadores de ttx-s.
CL2012000967A1 (es) Compuestos derivados de amida de los acidos indazol-4-carboxilico y 1-h-pirazolo[3,4-c]piridina-4-carboxilico, agonistas del receptor ccr1; composicion farmaceutica; utiles en el tratamiento de inflamaciones cronicas, alergias, soriasis, artritis reumatoidea, esclerosis multiple, diabetes tipo 1, entre otras.
NZ738990A (en) Cgrp receptor antagonists
CL2007002643A1 (es) Compuestos derivados de 5-fenil-nicotinamida, moduladores del receptor de cb1; procedimiento de preparacion; composiciones farmaceuticas; y uso para el tratamiento y/o profilaxis de trastornos de la nutricion, diabetes tipo ii y dependencia de sustan